Cargando…
ChAdOx1 nCoV-19 Immunogenicity and Immunological Response Following COVID-19 Infection in Patients Receiving Maintenance Hemodialysis
Patients with end-stage renal disease (ESRD) receiving hemodialysis (HD) were found to have a decreased immune response following mRNA COVID-19 immunization. ChAdOx1 nCoV-19 was a promising COVID-19 vaccine that performed well in the general population, but the evidence on immunogenicity in ESRD wit...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9230560/ https://www.ncbi.nlm.nih.gov/pubmed/35746567 http://dx.doi.org/10.3390/vaccines10060959 |
_version_ | 1784735090773852160 |
---|---|
author | Prasithsirikul, Wisit Nopsopon, Tanawin Phutrakool, Phanupong Suwanwattana, Pawita Kantagowit, Piyawat Pongpirul, Wannarat Jongkaewwattana, Anan Pongpirul, Krit |
author_facet | Prasithsirikul, Wisit Nopsopon, Tanawin Phutrakool, Phanupong Suwanwattana, Pawita Kantagowit, Piyawat Pongpirul, Wannarat Jongkaewwattana, Anan Pongpirul, Krit |
author_sort | Prasithsirikul, Wisit |
collection | PubMed |
description | Patients with end-stage renal disease (ESRD) receiving hemodialysis (HD) were found to have a decreased immune response following mRNA COVID-19 immunization. ChAdOx1 nCoV-19 was a promising COVID-19 vaccine that performed well in the general population, but the evidence on immunogenicity in ESRD with HD patients was limited. Moreover, the immunological response to COVID-19 infection was inconclusive in patients with ESRD and HD. The aim of this study was to investigate the immunogenicity of ChAdOx1 nCoV-19 vaccination and the immunological response after COVID-19 infection in ESRD patients with HD. The blood samples were obtained at baseline, 1-month, and 3-month follow-up after each shot or recovery. All participants were measured for anti-spike IgG by the ELISA method, using Euroimmun. This study found a significant increase in anti-spike IgG after 1 month of two-shot ChAdOx1 nCoV-19 vaccination, followed by a significant decrease after 3 months. On the other hand, the anti-spike IgG was maintained in the post-recovery group. There was no significant difference in the change of anti-spike IgG between the one-shot ChAdOx1 nCoV-19-vaccinated and post-recovery groups for both 1-month and 3-month follow-ups. The seroconversion rate for the vaccinated group was 60.32% at 1 month after one-shot vaccination and slightly dropped to 58.73% at the 3-month follow-up, then was 92.06% at 1 month after two-shot vaccination and reduced to 82.26% at the 3-month follow-up. For the recovered group, the seroconversion rate was 95.65% at 1 month post-recovery and 92.50% at 3-month follow-up. This study demonstrated the immunogenicity of two-dose ChAdOx1 nCoV-19 in ESRD patients with HD for humoral immunity. After COVID-19 infection, the humoral immune response was strong and could be maintained for at least three months. |
format | Online Article Text |
id | pubmed-9230560 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-92305602022-06-25 ChAdOx1 nCoV-19 Immunogenicity and Immunological Response Following COVID-19 Infection in Patients Receiving Maintenance Hemodialysis Prasithsirikul, Wisit Nopsopon, Tanawin Phutrakool, Phanupong Suwanwattana, Pawita Kantagowit, Piyawat Pongpirul, Wannarat Jongkaewwattana, Anan Pongpirul, Krit Vaccines (Basel) Article Patients with end-stage renal disease (ESRD) receiving hemodialysis (HD) were found to have a decreased immune response following mRNA COVID-19 immunization. ChAdOx1 nCoV-19 was a promising COVID-19 vaccine that performed well in the general population, but the evidence on immunogenicity in ESRD with HD patients was limited. Moreover, the immunological response to COVID-19 infection was inconclusive in patients with ESRD and HD. The aim of this study was to investigate the immunogenicity of ChAdOx1 nCoV-19 vaccination and the immunological response after COVID-19 infection in ESRD patients with HD. The blood samples were obtained at baseline, 1-month, and 3-month follow-up after each shot or recovery. All participants were measured for anti-spike IgG by the ELISA method, using Euroimmun. This study found a significant increase in anti-spike IgG after 1 month of two-shot ChAdOx1 nCoV-19 vaccination, followed by a significant decrease after 3 months. On the other hand, the anti-spike IgG was maintained in the post-recovery group. There was no significant difference in the change of anti-spike IgG between the one-shot ChAdOx1 nCoV-19-vaccinated and post-recovery groups for both 1-month and 3-month follow-ups. The seroconversion rate for the vaccinated group was 60.32% at 1 month after one-shot vaccination and slightly dropped to 58.73% at the 3-month follow-up, then was 92.06% at 1 month after two-shot vaccination and reduced to 82.26% at the 3-month follow-up. For the recovered group, the seroconversion rate was 95.65% at 1 month post-recovery and 92.50% at 3-month follow-up. This study demonstrated the immunogenicity of two-dose ChAdOx1 nCoV-19 in ESRD patients with HD for humoral immunity. After COVID-19 infection, the humoral immune response was strong and could be maintained for at least three months. MDPI 2022-06-16 /pmc/articles/PMC9230560/ /pubmed/35746567 http://dx.doi.org/10.3390/vaccines10060959 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Prasithsirikul, Wisit Nopsopon, Tanawin Phutrakool, Phanupong Suwanwattana, Pawita Kantagowit, Piyawat Pongpirul, Wannarat Jongkaewwattana, Anan Pongpirul, Krit ChAdOx1 nCoV-19 Immunogenicity and Immunological Response Following COVID-19 Infection in Patients Receiving Maintenance Hemodialysis |
title | ChAdOx1 nCoV-19 Immunogenicity and Immunological Response Following COVID-19 Infection in Patients Receiving Maintenance Hemodialysis |
title_full | ChAdOx1 nCoV-19 Immunogenicity and Immunological Response Following COVID-19 Infection in Patients Receiving Maintenance Hemodialysis |
title_fullStr | ChAdOx1 nCoV-19 Immunogenicity and Immunological Response Following COVID-19 Infection in Patients Receiving Maintenance Hemodialysis |
title_full_unstemmed | ChAdOx1 nCoV-19 Immunogenicity and Immunological Response Following COVID-19 Infection in Patients Receiving Maintenance Hemodialysis |
title_short | ChAdOx1 nCoV-19 Immunogenicity and Immunological Response Following COVID-19 Infection in Patients Receiving Maintenance Hemodialysis |
title_sort | chadox1 ncov-19 immunogenicity and immunological response following covid-19 infection in patients receiving maintenance hemodialysis |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9230560/ https://www.ncbi.nlm.nih.gov/pubmed/35746567 http://dx.doi.org/10.3390/vaccines10060959 |
work_keys_str_mv | AT prasithsirikulwisit chadox1ncov19immunogenicityandimmunologicalresponsefollowingcovid19infectioninpatientsreceivingmaintenancehemodialysis AT nopsopontanawin chadox1ncov19immunogenicityandimmunologicalresponsefollowingcovid19infectioninpatientsreceivingmaintenancehemodialysis AT phutrakoolphanupong chadox1ncov19immunogenicityandimmunologicalresponsefollowingcovid19infectioninpatientsreceivingmaintenancehemodialysis AT suwanwattanapawita chadox1ncov19immunogenicityandimmunologicalresponsefollowingcovid19infectioninpatientsreceivingmaintenancehemodialysis AT kantagowitpiyawat chadox1ncov19immunogenicityandimmunologicalresponsefollowingcovid19infectioninpatientsreceivingmaintenancehemodialysis AT pongpirulwannarat chadox1ncov19immunogenicityandimmunologicalresponsefollowingcovid19infectioninpatientsreceivingmaintenancehemodialysis AT jongkaewwattanaanan chadox1ncov19immunogenicityandimmunologicalresponsefollowingcovid19infectioninpatientsreceivingmaintenancehemodialysis AT pongpirulkrit chadox1ncov19immunogenicityandimmunologicalresponsefollowingcovid19infectioninpatientsreceivingmaintenancehemodialysis |